Depression Treatment Nears Approval After Trial Success

Millions of people battling treatment-resistant depression may soon have a powerful new option that works in days, not weeks.

Compass Pathways announced their investigational therapy COMP360 successfully completed two Phase III trials for treatment-resistant depression, a condition affecting people who haven't responded to standard antidepressants. The synthetic psilocybin-based treatment reduced depression scores significantly more than a control dose, with benefits appearing as quickly as one day after administration.

In the COMP006 trial, patients who received a 25mg dose experienced a 3.8-point improvement on standard depression scales compared to those receiving a minimal 1mg dose. Even more encouraging, 39% of patients showed clinically meaningful improvements at six weeks after receiving just two doses three weeks apart.

The COMP005 trial revealed the therapy's staying power. A quarter of patients who received the 25mg dose maintained meaningful depression improvements for 26 weeks after only one or two treatment sessions.

Both trials confirmed the therapy's safety profile. The most common side effects included headache, nausea, anxiety and visual hallucinations, with serious adverse events occurring in less than 5% of patients across both studies.

The Ripple Effect

This breakthrough could transform how doctors approach severe depression treatment. Unlike Spravato, the only other recently approved alternative that requires ongoing intranasal doses, COMP360 works with a finite course of just one to two supervised sessions.

The timing couldn't be better for mental health infrastructure. Clinics that have already adapted to provide Spravato treatments now have the facilities and trained staff ready to offer psilocybin therapy, potentially speeding patient access if approved.

Compass plans to submit their application to the FDA in late 2026 and aims to be commercially ready by year's end. If approved, COMP360 would become the first classic psychedelic treatment authorized for mental health conditions, opening doors for an entire class of promising therapies.

Analysts forecast the therapy could generate $879 million in sales by 2031, reaching thousands of people who've exhausted other options.

After decades of stigma, psychedelic medicine is finally getting its moment to help those who need it most.